Sage Therapeutics/Biogen's Episodic Therapy Zuranolone Could Change MDD Treatment

Yahoo FinanceJul 22 01:12 ET

Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Evercore

BenzingaJul 19 09:39 ET

Mizuho Securities Lowers Adjusts Price Target on Sage Therapeutics to $16 From $18, Maintains Neutral Rating

Sage Therapeutics (SAGE) has an average hold rating and price target range of $8 to $70, according to analysts polled by Capital IQ.Price: 12.41, Change: +0.23, Percent Change: +1.93

MT NewswiresJul 19 09:37 ET

Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $18

Mizuho Securities analyst Uy Ear maintains $Sage Therapeutics(SAGE.US)$ with a hold rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 40.4%

Moomoo NewsJul 19 07:34 ET · Ratings

Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

TipRanksJul 19 07:06 ET

Express News | Sage Therapeutics Inc : Mizuho Cuts Target Price to $16 From $18

ReutersJul 19 06:34 ET